Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-22-006664
Filing Date
2022-03-09
Accepted
2022-03-09 18:06:17
Documents
2
Period of Report
2022-02-14

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 5786
2 poa_ogden.htm EX-24 8577
  Complete submission text file 0001567619-22-006664.txt   15767
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address
Ogden Christopher (Reporting) CIK: 0001914523 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37587 | Film No.: 22726683